Post-Marketing Observational Surveillance Study to Evaluate the Occurrence of Acute Myocardial Infarction in Adults 18 Years of Age and Older Who Receive HEPLISAV-B® Compared with Another Hepatitis B Vaccine (DV2-HBV-25) First published 03/02/2023 Last updated 23/04/2024 EU PAS number:EUPAS50452 Study Finalised